Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21)
Korean Cancer Study Group (KCSG) Breast Cancer Committee
Research output: Contribution to journal › Article › peer-review
Fingerprint
Dive into the research topics of 'Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21)'. Together they form a unique fingerprint.
Medicine and Dentistry
Pharmacology, Toxicology and Pharmaceutical Science